Rowan Chapman Sells 2,964 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) Director Rowan Chapman sold 2,964 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $216.78, for a total value of $642,535.92. Following the completion of the sale, the director owned 3,124 shares in the company, valued at approximately $677,220.72. This trade represents a 48.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Natera Price Performance

NTRA stock opened at $231.41 on Friday. The stock has a market capitalization of $33.14 billion, a P/E ratio of -141.97 and a beta of 1.56. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $256.36. The business has a 50-day moving average of $207.79 and a 200-day moving average of $215.40.

Hedge Funds Weigh In On Natera

A number of institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its position in shares of Natera by 10.5% in the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after acquiring an additional 1,225,420 shares during the period. Wellington Management Group LLP raised its holdings in shares of Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after purchasing an additional 2,420,263 shares during the period. State Street Corp raised its holdings in shares of Natera by 2.2% in the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after purchasing an additional 72,087 shares during the period. Franklin Resources Inc. lifted its stake in Natera by 37.5% in the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after purchasing an additional 727,366 shares during the last quarter. Finally, Coatue Management LLC grew its holdings in Natera by 1,446.1% during the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after purchasing an additional 2,463,008 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently issued reports on NTRA shares. Morgan Stanley lowered their price objective on shares of Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. BTIG Research decreased their target price on shares of Natera from $260.00 to $250.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Piper Sandler reiterated an “overweight” rating and issued a $249.00 price target on shares of Natera in a research note on Tuesday, May 12th. Evercore reissued an “outperform” rating and set a $270.00 price target on shares of Natera in a research report on Friday, May 8th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and an average target price of $256.53.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.